EUVIMEDEUVIMED entdecken
Crossref

Metformin ameliorates trophoblastic immunometabolic disorders via attenuating TLR4/NF-κB signaling through ATXN7L3-mediated histone H2B monoubiquitination

Yang Zhang, Zhicheng Yu, Yin Zhao, Li Zou, Bin Deng, Xiaoxia Liu

Placenta · 2025

DOI: 10.1016/j.placenta.2025.03.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Placenta, 2025. Verfasst von Yang Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Prenata…. Hauptthemen laut MEDLINE: Trophoblasts, Toll-Like Receptor 4, NF-kappa B, Metformin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Nature Science Foundation of China, Hubei Provincial Natural Science Foundation, Science foundation of union hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Trophoblastic inflammation and glycometabolic reprogramming represent two hallmarks of numerous diverse placental disorders, including but not limited to preterm labor, preeclampsia, and fetal growth restriction. Recent evidence indicates that TLR4/NF-κB signaling mediate the interaction between trophoblastic inflammation and glycometabolism disturbance while pharmacologic doses of metformin (MET, 10 μM) corrected these vicious states via its suppression on this pathway. However, the underlying precise mechanism remain incompletely understood. METHODS: ATXN7L3 was identified through comprehensive proteomic screening. The oxidative phosphorylation and glycolysis were detected to evaluate the metabolic reprogramming. ELISA and adhesion experiment were used to evaluate the trophoblastic inflammation. Chromatin immunoprecipitation assay and co-immunoprecipitation assays were used to clarify the precise mechanism of MET on TLR4/NF-κB signaling. RESULTS: MET corrected trophoblastic glycometabolic reprogramming and attenuated excessive inflammation via ATXN7L3. Mechanistically, MET regulated the TLR4/NF-κB signaling pathway through ATXN7L3-mediated Histone H2B monoubiquitylation. CONCLUSIONS: Our findings elucidate a novel epigenetic regulatory mechanism whereby pharmacologic doses of MET ameliorated the TLR4/NF-κB signaling-induced immunometabolic disorders in trophoblasts through ATXN7L3-mediated H2Bub1. This study exploratively elucidated a novel mechanism underlying MET's pharmacological effects and provided novel insights into its role in ameliorating placental immunometabolism and development, potentially offering a novel pharmacological strategy for treating preeclampsia, fetal growth restriction, and related obstetrical syndromes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrophoblastsToll-Like Receptor 4NF-kappa BMetforminHistonesHypoglycemic AgentsHumansSignal TransductionFemalePregnancyUbiquitination

Stichwörter der Autor:innen

ATXN7L3GlycometabolismH2Bub1InflammationMetforminPlacenta

Substanzen

Toll-Like Receptor 4NF-kappa BMetforminHistonesTLR4 protein, humanHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Prenatal Diagnosis Center, Union Hospital, Tongji Medical College, Huazhong U…
  • Department of Obstetrics and Gynecology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
  • Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: dengbin@hust.edu.cn.

Förderung

  • National Nature Science Foundation of China
  • Hubei Provincial Natural Science Foundation
  • Science foundation of union hospital
  • USTC Research Funds of the Double First-Class Initiative
  • Wuhan Union Hospital
  • Hubei Province Natural Science Foundation
  • National Natural Science Foundation of China
  • USTC

Zitieren

APA

Zhang, Y., Yu, Z., Zhao, Y., Zou, L., Deng, B., & Liu, X. (2025). Metformin ameliorates trophoblastic immunometabolic disorders via attenuating TLR4/NF-κB signaling through ATXN7L3-mediated histone H2B monoubiquitination. Placenta. https://doi.org/10.1016/j.placenta.2025.03.020

Vancouver

Zhang Y, Yu Z, Zhao Y, Zou L, Deng B, Liu X. Metformin ameliorates trophoblastic immunometabolic disorders via attenuating TLR4/NF-κB signaling through ATXN7L3-mediated histone H2B monoubiquitination. Placenta. 2025. doi:10.1016/j.placenta.2025.03.020

BibTeX
@article{Zhang2025,
  author = {Zhang, Yang and Yu, Zhicheng and Zhao, Yin and Zou, Li and Deng, Bin and Liu, Xiaoxia},
  title = {Metformin ameliorates trophoblastic immunometabolic disorders via attenuating TLR4/NF-κB signaling through ATXN7L3-mediated histone H2B monoubiquitination},
  journal = {Placenta},
  year = {2025},
  doi = {10.1016/j.placenta.2025.03.020}
}
Kostenlos starten →